UroGen Pharma (URGN) Net Cash Flow (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Net Cash Flow data on file, last reported at -$800000.0 in Q1 2026.

• Quarterly Net Cash Flow rose 98.82% year-over-year to -$800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (up 122.78% YoY) and the FY2025 annual result came in at -$61.0 million, down 178.93% from the prior year.
• Net Cash Flow slipped to -$800000.0 in Q1 2026, from $20.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $99.2 million in Q3 2023 to a low of -$94.8 million in Q3 2024.
• A 5-year average of $3.9 million and a median of -$2.6 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 551.35% — and 2024, when it soared 639.49%.
• Tracing URGN's Net Cash Flow over 5 years: stood at $26.7 million in 2022, then plunged by 190.93% to -$24.3 million in 2023, then surged by 293.72% to $47.1 million in 2024, then slumped by 56.01% to $20.7 million in 2025, then tumbled by 103.86% to -$800000.0 in 2026.
• The last three Net Cash Flow figures came in at -$800000.0 (Q1 2026), $20.7 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.